FDA Brief

Warning letters Drugs

FDA warning letter to

Grupo Quimico SRL

High riskIssued Apr 30, 2024Posted May 14, 2024Center for Drug Evaluation and Research | CDER

FDA warns Uruguay contract testing lab Grupo Quimico over data integrity failures, including unreported failing HPLC results.

What happened

FDA inspected Grupo Quimico's contract testing laboratory in Montevideo from November 20 to 22, 2023. The agency found that laboratory records did not include all testing data, including unprocessed and unreported HPLC sample injections that later proved out-of-specification for ingredient assay. FDA also found manual integration not indicated, inadequate procedures for electronic data review, and HPLC systems without audit trails or controls to prevent data deletion.

What FDA found

  1. The lab did not keep complete laboratory records showing all test data, including unreported out-of-specification HPLC results and manual integration.

    21 CFR 211.194(a)
  2. The lab lacked adequate procedures for collecting, reviewing, and integrating electronic data and for HPLC system suitability.

    21 CFR 211.160(b)
  3. The lab did not properly control its computer systems; analysts could delete HPLC data, and two systems lacked audit trails.

    21 CFR 211.68(b)

What FDA wants

FDA tells Grupo Quimico to correct the violations promptly and respond in writing within 15 working days with investigations, a risk assessment, a CAPA plan, and third-party assessments; if more time is needed, it must explain the delay and give a schedule.

Who should pay attention

  • drug manufacturers that use contract testing laboratories
  • US importers and agents for drugs tested by Grupo Quimico
  • quality teams relying on third-party analytical results

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk